STOCK TITAN
  1. Home
  2. News
  3. GRCL

Gracell Biotechnologies Inc - GRCL STOCK NEWS

Welcome to our dedicated news page for Gracell Biotechnologies (Ticker: GRCL), a resource for investors and traders seeking the latest updates and insights on Gracell Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gracell Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gracell Biotechnologies's position in the market.

News
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Gracell Biotechnologies to participate in two investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
conferences
-
News
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Rhea-AI Summary
Gracell Biotechnologies Inc. (GRCL) reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates. The company commenced Phase 1b/2 clinical trial in the U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM), and patient screening is underway. They also closed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
earnings
-
News
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Rhea-AI Summary
Gracell Biotechnologies announces oversubscribed $100 million financing with potential for an additional $50 million tied to exercise of warrants. The financing is expected to extend cash runway into the second half of 2026. Gracell intends to use the funds for research and development of its clinical-stage product candidates and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.99%
Tags
none
News
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences earnings
-
News
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
conferences
-
News
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
Rhea-AI Summary
Gracell Biotechnologies Inc. will participate in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York, NY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
conferences
News
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Rhea-AI Summary
Gracell Biotechnologies presented data on their CD19/BCMA dual-targeting FasTCAR-T GC012F therapy for the treatment of B-cell non-Hodgkin’s Lymphoma (B-NHL) at the EHA2023 Congress. The data showed a 100% overall response rate (ORR) and a 66.7% complete response (CR) rate at 6 months among treated patients. GC012F also demonstrated a favorable safety profile. Gracell is also evaluating GC012F in other indications such as relapsed/refractory multiple myeloma (RRMM) and systemic lupus erythematosus (SLE).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
Rhea-AI Summary
Gracell Biotechnologies presented long-term follow-up data on their GC012F therapy for the treatment of multiple myeloma at the ASCO Annual Meeting. The data showed impressive clinical outcomes, including a 93.1% overall response rate and 82.8% achieving minimal residual disease negativity. The therapy demonstrated durable responses with a median duration of response of 37.0 months and a median progression-free survival of 38.0 months. No new safety findings were reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
conferences
News
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.31%
Tags
conferences
Stock GRCL logo
Gracell Biotechnologies Inc

Nasdaq:GRCL

GRCL Rankings

N/A Ranked by Market Cap
#1945 Ranked by Stock Gains
N/A Ranked by Dividends

GRCL Stock Data

989.87M
165.04M
16.39%
63.11%
1.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Suzhou

About GRCL

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.